比例失衡分析中的陷阱:识别与规避
本文以VigiBase和IC为例,说明比例失衡分析在药物警戒信号检测中常因混杂、效应修饰、报告偏倚等被误用而得出错误结论。该分析应起支持而非决定性作用,需谨慎设计、解读并结合亚组与临床评估,同时需开发偏倚检测工具。
要点
- 比例失衡分析易受混杂、效应修饰、报告偏倚等影响,可产生虚假或遗漏信号。
- 复杂分析可能引入碰撞偏倚或放大掩蔽效应,亚组分析虽可缓解部分陷阱但会降低样本量。
- 比例失衡分析在信号检测中仅起支持作用,需结合临床评估谨慎解读。
核心结论
- 比例失衡分析因存在多种陷阱,在信号检测与评估中起支持而非决定性作用。
- 需谨慎设计、解读比例失衡分析,并结合适当亚组分析和临床评估。
研究设计与样本
- 使用VigiBase(WHO全球不良事件报告数据库)和Information Component(IC)比例失衡指标,提供示例说明常见错误来源。
主要发现
- 常见错误来源包括:混杂(年龄、性别、适应证、合并用药)、效应修饰(年龄)、名声偏倚、掩蔽、错误分类(编码错误、事件检索不完整或不精确)、忽视报告效用及违反独立性假设。
- 复杂分析可能引入新偏倚或放大现有偏倚,如碰撞偏倚或掩蔽放大。
临床怎么用
- 临床应用比例失衡分析时应审慎设计,结合亚组分析和临床评估解读结果。
- 亚组分析可缓解部分陷阱,但会减少样本量并可能引入或放大偏倚,需谨慎使用。
局限性
- 需进一步开发检测和缓解比例失衡分析中偏倚的工具,以及评估其偏倚风险的工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disproportionality analysis is used by many pharmacovigilance organizations for detecting and assessing signals of potential adverse drug reactions. However, its goal is often misunderstood and the approach misapplied, leading to erroneous conclusions due to neglected violated assumptions. In this paper we illustrate how simplistic use and interpretation of disproportionality analysis can lead to incorrect conclusions. Using VigiBase, the WHO global database of adverse event reports, and the Information Component disproportionality metric, we provide selected examples to highlight common sources of error that can introduce spurious disproportionalities or lead to missing important signals: confounding (by age, sex, indication, comedication), effect modification (by age), notoriety bias, masking, misclassification (by miscoding, incomplete or imprecise event retrieval), neglecting report utility, and violated independence assumption. Additionally, we present how sophisticated analyses may introduce new biases or amplify existing ones, such as collider bias or masking amplification. Due to its pitfalls, disproportionality analysis plays a supportive rather than decisive role in signal detection and assessment. Careful design and interpretation of disproportionality analysis, with appropriate subgrouping and clinical assessment, are essential. While subgrouping can mitigate some pitfalls, it reduces sample size and may introduce or amplify existing biases and needs to be used with care. Further development of tools to detect and mitigate biases in disproportionality analyses, and to assess their risk of bias, is needed.
引用
- Fusaroli M, Sartori D, van Puijenbroek EP, et al. Charting and Sidestepping the Pitfalls of Disproportionality Analysis. Drug Saf. 2025. PMID: 40993470. doi:10.1007/s40264-025-01604-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。